RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 SIGNIFY: Treatment with Ivabradine Does Not Improve Outcomes and May Increase Risk in Patients with Angina
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 13
OP 14
DO 10.1177/155989771427006
UL http://mdc.sagepub.com/content/14/27/13.abstract
AB This article presents the results of the Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Without Heart Failure [SIGNIFY; Fox K et al. N Engl J Med. 2014]. The study found that treatment with ivabradine did not reduce the risk of cardiovascular (CV) death or nonfatal myocardial infarction (NFMI). However, in patients with Canadian Cardiovascular Society class II or greater angina at baseline, ivabradine increased the risk of CV death or myocardial infarction.